ZRANB3

Across TCGA pan-cancer cohorts, ZRANB3 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated ZRANB3 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher ZRANB3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZRANB3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

MESO, LUAD, and STAD are the cancer types where ZRANB3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.098	0.579	.001	36	view →
LUAD	OS	Median	All	0.217	0.688	<.001	27	view →
STAD	OS	Median	II,III,IV	0.183	0.660	.009	12	view →
UCEC	DFS	Median	II,III,IV	0.906	0.306	.027	8	view →
GBM	DFS	Median	All	1.000	0.191	.022	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SARC	DFS	Median	All	0.168	0.614	.003	6	view →
SKCM	OS	Median	III,IV	0.245	0.721	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ZRANB3–MESO (OS)

Open the MESO breakdown →